Home › Funds › EcoR1 Capital, LLC › TRAX
EcoR1 Capital, LLC position in TRAX
FIRST TRACKS BIOTHERAPEUTICS · Health Care
EcoR1 Capital, LLC reported holding 3,174,519 shares of TRAX (FIRST TRACKS BIOTHERAPEUTICS) in its Q3 2026 13F filing — a position valued at US$112.5M, representing 5.33% of its reported portfolio and ranking #5 among its reported holdings. EcoR1 Capital, LLC has disclosed TRAX holdings in 2 of the last 2 reported quarters, going back to Q2 2026.
Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR
How EcoR1 Capital, LLC's TRAX position evolved
EcoR1 Capital, LLC first disclosed a stake in TRAX in Q2 2026 at 3,174,519 shares (US$63.9M). The position peaked in Q3 2026 at 3,174,519 shares, worth US$112.5M. Across 2 filings, EcoR1 Capital, LLC held the position steady without any share-count change. The most recent filing (Q3 2026) shows 3,174,519 shares valued at US$112.5M.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2026 | 3.17M | $63.87M | New |
| Q3 2026 | 3.17M | $112.50M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About TRAX and 13F data
TRAX (FIRST TRACKS BIOTHERAPEUTICS) is a Health Care company. 181 other funds we track also report a position in TRAX — the largest reported positions include TCG Crossover Management, LLC (US$102.6M), Affinity Asset Advisors, LLC (US$73.7M), Sanofi (US$29.1M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding TRAX
- TCG Crossover Management, LLC 2.90M sh · $102.61M · Q3 2026
- Affinity Asset Advisors, LLC 2.08M sh · $73.72M · Q3 2026
- Sanofi 821.92K sh · $29.13M · Q3 2026
- Trails Edge Capital Partners, LP 814.00K sh · $28.85M · Q3 2026
- STEMPOINT CAPITAL LP 649.92K sh · $23.03M · Q3 2026
- 683 Capital Management, LLC 600.00K sh · $21.26M · Q3 2026
- Vestal Point Capital, LP 1.01M sh · $20.38M · Q2 2026
- Sofinnova Investments, Inc. 383.59K sh · $13.59M · Q3 2026
- Palo Alto Investors LP 603.49K sh · $12.14M · Q2 2026
- Ally Bridge Group (NY) LLC 284.29K sh · $5.72M · Q2 2026
- Opaleye Management Inc. 65.00K sh · $1.31M · Q2 2026
More on EcoR1 Capital, LLC
FAQ
How long has EcoR1 Capital, LLC held TRAX?
EcoR1 Capital, LLC has disclosed TRAX holdings in 2 of the last 2 reported quarters, going back to Q2 2026.
What is EcoR1 Capital, LLC's current position in TRAX?
As of Q3 2026, EcoR1 Capital, LLC holds 3.17M shares of TRAX (FIRST TRACKS BIOTHERAPEUTICS), valued at $112.50M, representing 5.33% of its reported portfolio and ranking #5.
Has EcoR1 Capital, LLC been buying or selling TRAX?
In the latest 13F filing (Q3 2026), EcoR1 Capital, LLC held unchanged its position in TRAX. The position peaked in Q3 2026 at 3.17M shares.
Which other funds hold TRAX?
Other major institutional holders of TRAX include TCG Crossover Management, LLC, Affinity Asset Advisors, LLC, Sanofi, among 181 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.